Verity A Saunders - Concepedia

Author

Verity A Saunders

Also Known As

Phuong Dang, V A Saunders, V Saunders, V. Saunders, V.A. Saunders, Verity A Saunders, Verity A. Saunders, Verity Ann Saunders, Verity Saunders

Publications

2.5K

Citations

H-Index

Concepts

All Affiliations

The University of Adelaide South Australia Pathology Centre for Cancer Biology South Australian Health and Medical Research Institute Australasian Leukaemia and Lymphoma Group

About

Verity A Saunders is an author at The University of Adelaide specializing in medicine, cell biology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	230
2	Cell Biology	5	5	180
3	Engineering	1	1	14
4	Health Sciences	1	1	24
5	Epidemiology	1	1	128

Verity A Saunders

Publications

2.1K

Citations

H-Index

Page 1

	Year	Citations
OCT-1–mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib Deborah L. White, Verity A Saunders, Phuong Dang, Blood	2006	430
Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity Deborah L. White, Verity A Saunders, Phuong Dang, Blood	2007	330
Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications Devendra Hiwase, Verity A Saunders, D. Hewett, Clinical Cancer Research	2008	218
Functional Activity of the OCT-1 Protein Is Predictive of Long-Term Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib Deborah L. White, Phuong Dang, Jane R. Engler, Journal of Clinical Oncology	2010	182
In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML Deborah L. White, Verity A Saunders, A. Bruce Lyons, Blood	2005	145
Mortality in Ulcerative Colitis S N Gyde, P Prior, M. J. Dew, Gastroenterology EpidemiologyGastroenterologyUlcerative Colitis	1982	128
Measurement of In Vivo BCR-ABL Kinase Inhibition to Monitor Imatinib-Induced Target Blockade and Predict Response in Chronic Myeloid Leukemia Deborah L. White, Verity A Saunders, Andrew Grigg, Journal of Clinical Oncology	2007	70
Chronic Myeloid Leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 Activity J R Engler, Amity Frede, Verity A Saunders, Leukemia Hematological MalignancyChromatinMixed-phenotype Acute LeukemiaImmunologyHematology	2010	60
The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression <i>in vitro</i> Laura N Eadie, Verity A Saunders, Susan Branford, Oncotarget	2018	57
Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors Devendra Hiwase, Deborah L. White, Jason A. Powell, Leukemia InflammationCytokineSignal TransductionCell RegulationReceptor Tyrosine Kinase	2010	56

Page 1